Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Trending

Thistle extract was tied to a large drop in a liver enzyme in a meta-analysis of 221 patients — but all had alcoholic liver disease and the dose used wasn't reported.

The result is promising for a specific clinical population, but with only 6 small studies and a moderate strength of evidence, it's far from a general recommendation for healthy people.

A meta-analysis found that silibinin (from thistle) significantly reduced ALT, a marker of liver stress, in people with alcoholic liver disease. However, the analysis pooled just 221 patients from six studies, the dose was not specified, and mild side effects like stomach upset and insomnia were reported.

Where this fits in the evidence

Pillser has synthesized 6 studies on Thistle for Reduced Alanine Aminotransferase Level — overall evidence strength: Moderate.

Across 6 studies (4 beneficial, 2 neutral), thistle (silymarin) shows mixed evidence for reducing alanine aminotransferase (ALT) levels, with effect sizes ranging from small to large. The strongest evidence comes from meta-analyses in clinical populations with liver conditions (NAFLD, alcoholic liver disease, anti-tuberculosis drug-induced liver injury). Median study duration was approximately 15 weeks across the two studies that reported it, but dose information is limited.

This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.

Back to top